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The work in the thesis entitled “Novel Pyrrolo[2,1-c][1,4]benzodiazepine--Glycoside Prodrugs for Selective Therapy of Cancer and Conformationally Restricted PBD Dimers as  DNA Binding Anticancer Agents” has been undertaken with an aim to synthesize novel PBD molecules, for targeted delivery of the active moiety at the tumour site selectively and PBD dimers with enhanced DNA binding efficiency. The work carried out has been described in four chapters.

Chapter I: This chapter gives general introduction to cancer and its chemotherapy, covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics. It also gives an introduction to prodrugs and their classification and the objectives of present work.

Chapter II: This chapter deals with general introduction to antibody directed enzyme prodrug therapy (ADEPT), gene directed enzyme prodrug therapy (GDEPT) and prodrug mono therapy (PMT) strategies for selective therapy of cancer and recent developments in the area of prodrugs for selective therapy of cancer, followed by the description of design, synthesis and biological evaluation of PBD-galactoside prodrugs for targeted delivery of the active molecule at the tumour site with a potential for selective therapy of solid tumours, particularly the hepatocellular carcinoma, by ADEPT, GDEPT and PMT strategies. 

Chapter III: This chapter illustrates the importance of the enzyme -glucuronidase in selective treatment of solid tumours and also describes the synthesis and biological evaluation of PBD-glucuronide prodrugs for enhanced tumour selectivity by PMT, ADEPT and GDEPT strategies. 

Chapter IV: This chapter describes the design, synthesis and DNA binding affinities of novel conformationally restricted 1,4-cis and trans pyrrolobenzodiazepine dimers that are envisioned to possess improved DNA binding affinity. 
Chapter- I
General introduction to cancer, pyrrolobenzodiazepines as anticancer agents and prodrugs

Cancer is one of the dreadful diseases, which remained as a challenge to both physicians as well as scientists. Every year more than 20% of the population is affected by cancer and the rate of its induction throughout the world is increasing every year, making it an area of major focus for researchers. Cancer is not a single disease but a broad group, characterized by uncontrolled proliferation and spread of aberrant cells from their site of origin. At the simplest level, cancer cells may be regarded as having lost touch with the rest of the environment of the body so that they are no longer responsive to the controlling signals and interactions that occur continuously in normal healthy tissues. Cancer cells have some important properties that underlie the nature of the agent that causes the disease.











Design, synthesis and biological evaluation of PBD-β-galactoside prodrugs for potential application in selective chemotherapy of solid tumours by ADEPT, GDEPT and PMT strategies

Chemists have long sought the “magic bullet” for the treatment of cancer, a compound that would selectively kill cancerous tissues without affecting healthy cells. Perhaps a more realistic objective is selective delivery of a cytotoxic agent to the cancer cells, in other words, to maximize the concentration of the cytotoxic agent at the tumour while minimizing its concentration around healthy tissues.
A major focus of the current drug research is to improve drug targeting to internal target sites such as to solid tumours or specific organs. The objective of drug targeting, especially for cancer chemotherapy, is to enhance the effectiveness of the drug by concentrating it at the target site and minimizing its effects at non-target sites. 









The delivery of PBD parent imines to the tumour site was expected to be enzyme specific i.e., the prodrug is activated to deliver the drug in the tissue, only in the presence of the enzyme β-galactosidase, leading to toxic effect. Two different cell lines, A375 and HepG2 were selected to probe the activation ability of the prodrugs by ADEPT and PMT strategies respectively. Therefore effective delivery of the drugs to the cells in the presence of externally administered E. Coli β-galactosidase was studied on human melanoma cell line A375.  The cells of Hep G2 are known to produce the enzyme β-galactosidase endogenously, and it was intended to exploit it, for selective therapy of hepatocellular carcinoma. The results were found accordingly, and the prodrugs were found to induce inhibition of cell division by the endogenous β-galactoside in HepG2 cells. The HepG2 cells were found to have toxic effect, by the activation of the prodrugs with the endogenous enzyme. These prodrugs have been found to be good substrates for use in PMT, ADEPT and GDEPT of solid tumours. The biological evaluation was made by CFSE antiproliferation assay.





Design, synthesis and biological evaluation of PBD-β-glucuronide prodrugs for potential application in selective chemotherapy of solid tumours by ADEPT and PMT strategies

The histochemical studies of the cancerous tissues have shown the presence of β-glucuronidase in considerably high quantities compared to the normal tissues. Cancer tissues of breast are also reported to possess high quantities of the enzyme endogenously, which could serve the purpose of activating the prodrugs selectively in the breast tumours selectively. 
In continuation of our efforts to develop prodrugs of PBD anticancer agents for application in selective therapy of cancer, prodrugs having the general structure pyrrolobenzodiazepine-spacer-β-glucuronide have been designed and synthesized for activation by the enzyme β-glucuronidase. PBD-glucuronide prodrugs were conceptualized and synthesized because of the hydrophilicity of this functional group, the ability of glucuronide prodrugs to be preferentially activated at tumour cells targeted with β-glucuronidase antibody conjugates (ADEPT), and the strong antitumour activity observed after combined treatment with glucuronide prodrugs and β-glucuronidase-antibody conjugates or fusion proteins in animal models. In addition, glucuronide prodrugs have potential for cancer prodrug monotherapy (PMT) of tumours that over express or accumulate lysosomal β-glucuronidase.









In conclusion PBD--glucuronide prodrugs with a potential for selective therapy of cancer have been developed.
Chapter- IV
Design, synthesis and DNA binding efficacy of novel conformationally restricted 1,4-cis/trans pyrrolo[2,1-c][1,4]benzodiazpine dimers

Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers are synthetic sequence-selective interstrand DNA minor-groove cross-linking agents developed from the monomeric anthramycin family of naturally occurring antitumour agents. One possible explanation for the biological activity of PBD dimers is that they bind sequence-selectively to critical genomic regions containing an over-abundance of relevant binding sites, thereby blocking transcription of key genes essential for tumour growth and/or inhibiting DNA replication. This concept has been used to explain the activity of other sequence-selective DNA-binding agents. An alternative explanation is that, compared to normal cells, tumour cells have an inherently reduced ability to repair such stable and complex interstrand cross-linked adducts across the entire genome and so enter an apoptotic pathway. 






In conclusion two new PBD dimers bridged by unsaturated, conformationally restricted chains have been designed synthesized and evaluated for DNA binding affinity, and were found to possess enhanced binding affinity compared to a saturated and conformationally free carbon chain bridged dimers. 
In conclusion the thesis describes the development of pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for selective therapy of cancer and novel PBD dimers, as DNA interactive anticancer agents.
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